A subgroup analysis was performed from data collected in a phase 3 study of intravenous ( IV ) fosaprepitant or oral aprepitant , plus the 5-HT 3 antagonist ondansetron and the corticosteroid dexamethasone , in cisplatin-nave patients with solid malignancies .